Drug firm Aurobindo Pharma Ltd today made an announcement that it has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Nafcillin injection a drug used for treating bacterial infections. Nafcillin for injection is a sterile semisynthetic penicillin (SSP) which is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have established susceptibility to the drug. It may be used prior to the availability of susceptibility test results to initiate therapy in suspected cases of resistant staphylococcal infections. The company will manufacture and market Nafcillin for injection USP packaged in 1g and
